# TABLE OF CONTENTS

## OUR COMPANY
- About Amneal  
  - About this Report
- Company Overview
- Our Commitment to Corporate Responsibility

## OUR PRODUCTS
- Our Portfolio
- Product Quality and Safety
- Distribution and Supply Chain

## SOCIAL
- Making Healthy Affordable
- Making Healthy Accessible
- Investment in Research and Development (R&D)
- Extending Access and Affordability to International Markets
- Our People
- Diversity, Equity, Inclusion and Belonging (DEIB)
- Culture of Learning, Listening and Acknowledgement
- Giving Back Globally

## ENVIRONMENT
- Global Environmental Working Group
- Tracking our Carbon Footprint
- Enhancing Environmental, Health and Safety (EHS)
- Making Healthy Possible for our Planet

## GOVERNANCE
- Board Diversity
- Our Corporate Compliance and Ethics Program
- Global Supplier Code of Conduct
- Cybersecurity
- Forward-Looking Statements

## Sustainability Accounting Standards Board (SASB) Index
We’re pleased to share our 2022 Environmental, Social, and Governance update as we celebrate more than 20 years of providing affordable and essential medications to the U.S. and now the world. Amneal’s founding was inspired by a desire to help patients access their medicines. That inspiration remains the core focus of our now significantly more diversified global business.

We make healthy possible. We achieve that purpose by continuously expanding our offerings in complex generics, specialty products, biosimilars, injectables and a growing international portfolio. And we leverage those portfolios to deliver value to millions of patients and families.

To help contextualize our contributions to a more sustainable world, this year’s report is mapped to the United Nations Sustainable Development Goals (UN SDGs) and highlights our alignment to Goal 3: Good Health and Wellbeing.

We’re particularly excited to contextualize our contributions in this manner because we’re deeply passionate about good health and wellbeing, and it fuels us to advance Amneal every day. That commitment is also reflected by our Amneal family of employees who drive our ability to touch lives, who produce the medicines delivering billions of dollars in savings to U.S. patients, who volunteer to pack hygiene and nutritional kits for thousands in need, who plant trees for the environment, who support their communities and who do so much more.

Last year, we celebrated a key milestone in our pursuit to expand access with the launch of our commercial portfolio in India. Today, we’re helping to write a new chapter in providing innovative, high-quality Specialty medicines for Indian patients and families. And we’re not stopping there. We are entering markets like India, Europe, China and Canada and our R&D teams are hard at work expanding our pipeline and portfolio to help make healthy possible in even more places around the world.

We believe that to make healthy possible, we must also have a healthy planet. So we are also advancing our ESG commitments, including sharpening our focus on environmental responsibility by preparing to track our global carbon footprint in support of building a sustainability roadmap and associated goals. As we move toward global alignment, we’re proud that our local teams are making incremental improvements each year with an eye on even cleaner, greener operations.

Setting the Stage for 2023

Looking ahead to 2023, Amneal’s growing commitment to delivering value in support of Good Health and Well-Being demonstrates our desire to be an even more important partner in the pursuit of a healthier global future.

We will continue to enhance our efforts to develop, deliver, donate, and safeguard more accessible and affordable treatments. We will continue to elevate and embrace our Amneal family of employees. We will continue to recognize the value of direct feedback, recognition, and rewards in fostering a strong company culture. And we will empower that culture, through good governance, to continue making meaningful contributions toward the health and wellbeing of our communities and planet.

We would like to thank our Amneal family of employees for your continued work and dedication to our mission. Your tireless commitment will help ensure Amneal has a strong and healthy future.

We share our additional thanks to patients, customers, suppliers, shareholders, and partners for your continued trust. You have our promise to continuously evolve our business to elevate the value we deliver to the world.

Sincerely,

A Message from our co-CEOs

Chirag Patel
Chintu Patel
Amneal Co-founders & Co-CEOs
Our Company

Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and affordable, and provide solutions for tomorrow’s health challenges. We are Amneal and We make healthy possible.
About Amneal

We make healthy possible®

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business with a broadening portfolio in institutional injectables, biosimilars and select international markets, a growing branded business, and a rapidly expanding distribution business with AvKARE. Together, we’re quickly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines.

Today, Amneal is much more than generic medicines. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation and more complex products, broadened our portfolios in new categories and allowed us to enter new geographies to expand access to medicines.

COMPANY OVERVIEW

7,600 employees around the world

#4 U.S. generics business

$10 billion* savings delivered to U.S. patients via Amneal’s generic and biosimilars medicines

~31% U.S. leadership* represented by women

270+ medicines in portfolio

20 billion unit manufacturing capacity

*Leadership is defined at the level of Director and above

**Amneal’s generic savings in the U.S. in 2021 was calculated by taking the total national savings estimated by the Association for Accessible Medicines¹ and determining Amneal’s market share by volume, data of which was derived from IQVIA.

¹ Association for Accessible Medicines, The U.S. Generic & Biosimilar Medicines Savings Report, September 2021
2022: A LOOK BACK

JANUARY
- Announced agreement to acquire Baclofen franchise from Saol Therapeutics
- Launched My Thyroid Universe mobile app
- Established Biosciences infrastructure with appointments of Harsher Singh as SVP, Biosciences & Sean McGowan as VP, Biosimilars Sales & Marketing

FEBRUARY
- Completed acquisition of Baclofen franchise & welcomed 21 new colleagues to Biosciences Commercial
- Amneal accepted leadership roles at Association for Accessible Medicines & International Generic and Biosimilar Medicines Association

MARCH
- U.S. FDA approved our biosimilar: RELEUKO® (filgrastim-ayow)
- Presented IPX203 Clinical Trial Data at the American Academy of Neurology Annual Meeting

APRIL
- FDA approved our biosimilar: ALYMSYS® (bevacizumab-maly)

MAY
- FDA approved our biosimilar: FYLNETRA™ (pegfilgrastim-pbbk)

JUNE
- Expanded Specialty portfolio with launch of LYVISPAH® (baclofen)
- Shyamakant Giri joined as President, India Business & Emerging Markets
- Released 2nd CSR Report
- Amneal accepted leadership role with U.S. Department of Commerce’s U.S.-India CEO Forum

AUGUST
- Deb Autor joined Board of Directors, elevating board diversity & expertise
- Opened first commercial offices in India
- Submitted IPX203 New Drug Application to FDA
- Celebrated our company’s 20th Anniversary

OCTOBER
- Launched first biosimilar: ALYMSYS® (bevacizumab-maly)

NOVEMBER
- Launched second biosimilar: RELEUKO® (filgrastim-ayow)

DECEMBER
- Global Leadership Meeting in New Jersey
- Amneal Leadership Lab
About this Report

This 2022 Environmental, Social and Governance (ESG) report builds on our 2021 Corporate Responsibility report and provides a look at our progress in 2022 as it relates to our ESG performance, including updates to our people data and sustainability programs. This report is mapped to the United Nations Sustainable Development Goals (UN SDGs) and includes a Sustainability Accounting Standards Board (SASB) index aligned with the Biotechnology and Pharmaceuticals Standard.

Unless otherwise stated, this report details our performance on ESG topics and contains nonfinancial disclosures covering the period from January 1, 2022, through December 31, 2022, and is subject to change.

Advancing the Sustainable Development Goals

The United Nations introduced the 17 Sustainable Development Goals (SDGs) in 2015 as part of the 2030 Agenda for Sustainable Development to end poverty and hunger, maintain a sustainable environment, and promote peace and prosperity for all. Amneal’s mission to improve health and well-being inherently aligns with the SDGs.

Amneal is primarily focused on contributing to Goal 3: Good Health and Well-Being. As a leading provider of medicines in the United States (U.S.), we offer treatments that address critical health needs. Amneal is dedicated to supporting healthy living for patients, communities, and the planet. We not only develop, manufacture and distribute medicines, but we also donate treatments to those in need and safeguard the well-being of our employees and communities.

We focus on addressing SDG 3.4 to reduce premature mortality from non-communicable diseases through prevention and treatment, and promote mental health and well-being. We also support several other SDGs, which are highlighted throughout this report. Some of these include:

Our Commitment to Corporate Responsibility

While we are pleased with the progress we have made over the last two years (when we began to formally report on our ESG strategies), we continue to strengthen our commitment to operating as a responsible business. Each year we review our progress and leverage our accomplishments as the basis for setting new goals – all to ensure we continue to operate as a responsible, transparent, and trusted company.

Based on the three pillars of environmental, social and governance responsibility, our plans for 2023 include:

- **Deepening our commitment to affordability and accessibility in support of Goal 3** by continuing to develop, deliver, donate, and safeguard more accessible and affordable treatments, expand our pipeline and portfolio to help make healthy possible in even more places around the world, and host our second global employee volunteering event focused on health and hygiene kit-making.

- **Enhancing our environmental stewardship** by convening our Global Environmental Working Group, quantifying our greenhouse gas (GHG) emissions baseline (Scope 1 and 2), and preparing to align our environmental disclosures with the Task Force on Climate-Related Financial Disclosures (TCFD) as part of our ongoing commitment to responsible environmental practices.

  - **Strengthening our dedication to diversity, equity, inclusion, and belonging (DEIB)** by expanding our AmnealWomen Employee Resource Group (ERG) pilot program to India, providing additional DEIB training for our leaders, and empowering our colleagues to foster a culture of inclusivity and belonging.

  - **Reinforcing our commitment to good governance, ethics, and compliance** through enhanced training, improved processes and policies, and ongoing communication on ethics and compliance throughout the year.

We welcome input from our stakeholders, including customers, colleagues, and local communities, as we continue to advance our strategy.
Our Products

We deliver affordable, essential medicines to patients across the U.S. and India, and we’re expanding into Europe, Canada and China. With approximately 270 medicines in our portfolio, our broad portfolio is the foundation from which we make healthy possible. Visit Amneal.com for the full catalog of Amneal’s U.S. products.
Our Portfolio

In the U.S., our diverse portfolio of approximately 260 medicines in our Generics segment provides patients with more affordable access to quality medicines. We are also excited about our work to bring patients more affordable biologic therapy options through our Biosciences area, which today includes a broad portfolio of institutional injectables as well as Amneal’s growing oncology biosimilars portfolio. Our growing Specialty business delivers products that meet important medical needs in central nervous system disorders, endocrinology, and other therapeutic categories. And we’re expanding our business across key international markets including India, Europe, Canada and China.

Our Generics business delivers trust, quality and value and is among the largest in the U.S. Over the last several years, we have consistently grown faster than the overall U.S. generics market by constantly innovating, moving up the value chain of product complexity and expanding our impact on patients.

We develop, manufacture, and commercialize complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals across a broad range of therapeutic categories. Our retail and institutional portfolio contains approximately 260 generic medicines, many of which represent difficult-to-manufacture products or products with a high barrier-to-entry such as oncologics, anti-infectives and supportive care to healthcare providers.

Our Specialty business meets important medical needs by delivering proprietary medicines to the U.S. market. We offer a growing and innovative portfolio in core therapeutic categories including central nervous system disorders (Parkinson’s Disease, Spasticity, Migraine), endocrinology (Hypothyroidism), and other therapeutic areas.

Our specialty products are marketed through skilled Specialty Sales & Marketing Teams, who call on neurologists, movement disorder specialists, endocrinologists and primary care physicians in key markets throughout the U.S.

Our Biosciences team, part of our Generics business, delivers a growing portfolio of biosimilars and specialty injectable products across multiple therapeutic areas, including movement disorders and oncology. We believe biosimilars are the next wave of affordable medicines, providing greater patient access and lower costs, and have been diligently focused on expanding and investing in our biosciences capabilities and portfolio*.

Learn more at www.amnealbiosciences.com.

*This site is intended only for U.S. residents. The information contained herein is provided for educational purposes only and is not intended to replace discussions with a licensed healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.
What is a Biosimilar?

A biosimilar is a biologic medicine that is highly similar to the reference product notwithstanding minor differences in clinically inactive components. According to the U.S. Food and Drug Administration (FDA), biosimilarity means there are no clinically meaningful differences between the biological product and the FDA-approved reference product in terms of the safety, purity, and potency.

Biosimilars derived from biologics – are from living organisms, such as living cells and are modified using biotechnology to produce the active substance of biological medicine. Biosciences offer extraordinary value for patients, providers, and payers. These complex products are the future of accessible medicine, which is why Amneal is working to further deepen our biosciences capabilities, starting with a broadening portfolio of biosimilar medications.

THE VALUE OF BIOSIMILARS

Biosimilars are projected to save an estimated $38.4 billion from 2021 to 2025. Lower costs also mean greater accessibility for patients who need it most. Biosimilars are approved according to the US FDA’s rigorous standards. Their safety is continually monitored through post-marketing surveillance.

*Projected U.S. Savings From Biosimilars, 2021–2025. Published in: American Journal of Managed Care, Volume 28, No. 7 (July 2022) Posted on RAND.org on January 26, 2022

Today, we commercialize three oncology biosimilars in the U.S.

Learn more about Amneal Biosciences at amnealbiosciences.com

I’m a builder. I want to see new frontiers explored. I want to see Amneal be the most customer friendly organization there is. We make the healthcare system sustainable, and biosimilars are an opportunity for us to really punctuate that for our patient community.  

– Harsher Singh
Senior Vice President, Biosciences
Product Quality and Safety

Amneal is built on a strong quality track record and commitment to the highest standards of quality. Since our founding in 2002, the FDA has conducted over 90 successful inspections of our sites.

Due to the potential impact on human health and well-being, our industry is subject to a high level of regulation. We strive to comply with all applicable laws and regulations in the jurisdictions in which we operate, including the regulations for current Good Manufacturing Practice, Good Clinical Practice, and Pharmacovigilance. We set the highest bar for our products, pipeline, operations, and service because patients’ lives depend on it.

We are focused on the safety and well-being of patients. To help us better understand drug safety profiles and deliver safe products, our Corporate Drug Safety team collects, reviews, and reports adverse events and other safety findings associated with the use of our investigational and commercial products to relevant regulatory authorities.

Learn more about our commitment to patient safety and well-being.

Our Quality culture is a core pillar of our success and is defined by our unwavering teamwide commitment to integrity, transparency and compliance.

- Integrity – We deliver quality pharmaceuticals that are safe and effective. We also do what’s right for our Amneal family and for the families we serve. This commitment to integrity enables us to maintain an exceptional level of trust with patients, customers, physicians and pharmacists.
- Transparency – We are open and honest with ourselves and with all the people who depend on us.
- Compliance – We consistently meet or exceed quality, industry, and global regulatory standards.

For each member of our team, ‘Quality’ is a mindset that helps us achieve our goal to make healthy possible. Every day, across all roles and functions, we embrace the idea that “Quality begins with me.” Key performance indicators validate our efforts and ensure that we’re always improving – for our family… and for yours.

Learn more about Quality Culture.
Distribution and Supply Chain

Amneal’s state-of-the-art facilities allow it to launch products into the market via reliable and scalable distribution.

Amneal’s primary distribution sales operations facilities in the U.S. are situated in Glasgow, Kentucky. With over 275k square feet of space, the operations are strategically located in close proximity to the UPS Centennial Hub and within the Central time zone, enabling Amneal to provide one-day ground delivery to a significant majority of its customers’ distribution centers. Amneal also handles distribution of Control Substances, CII, List 1 Chemical and CIII thru V from its Kentucky location, providing seamless control over these products throughout the supply chain. From complete EDI interaction to comprehensive case-level bar code tracking, Amneal maintains FDA Drug Quality and Security Act Serialization Guidelines and critical account and order information is available upon demand. Each Amneal warehouse is designed for maximum efficiency and compliance.

The Amneal distribution staff maintains consistent communication with the manufacturing teams to ensure optimal supply levels and works closely with the account management and customer response teams to provide accurate and timely fulfillment of customer orders.

Learn more about our passionate Customer Service Team.
To ensure Amneal is at the forefront of addressing critical supply chain concerns, in August 2022, we announced our support of the creation of a bipartisan Congressional Domestic Pharmaceutical Manufacturing Caucus in the U.S. House of Representatives, which focuses on securing America’s pharmaceutical supply chain by ensuring that critical medicines are manufactured in the U.S.

The pandemic and Ukraine war have highlighted the vital importance of a sustainable supply chain in the pharmaceutical industry. From raw materials to finished products, domestic manufacturing is critical for our U.S. supply chain and national security. We fully support the prioritization of essential medicines to be made in America. We see the formation of this caucus as a key step towards the potential for a more permanent legislative solution that can drive meaningful change across our supply chain.

– Chirag and Chintu Patel
Co-Chief Executive Officers

Accreditations such as the National Association of Boards of Pharmacy Drug Distributor Accreditation (DDA) acknowledge Amneal’s commitment to excellence in pharmaceuticals. The DDA plays a pivotal role in preventing counterfeit drugs and devices from entering the U.S. medical supply. The accreditation reflects our dedication as a client and patient-centric organization.

Learn more about our role in protecting the pharmaceutical supply chain.
Social

We make healthy possible. That’s a very powerful and inspiring reason to come to work. Every day, our colleagues deliver innovations in the affordability and accessibility of essential medicines. And every day, that pursuit touches the lives of countless patients, families and healthcare providers. We’re exceptionally proud to showcase our contributions within this section, aligned to the SDGs. And we’re even more excited to continue building upon them into the future.
We primarily serve the U.S. market with a large and growing portfolio of affordable medicines. But we are also making substantial progress in extending our commitment to access and quality to international markets where we can deliver true impact. Late last year, we celebrated the launch of our commercial portfolio in India, which is helping to write a new chapter in the availability of quality medicines in India. And we’ve got our eye on many other emerging markets where we can bring forward similar benefit.

We recognize that our people power our success. So we prioritize recruiting, empowering, incentivizing and rewarding a diverse cohort of employees. We also provide more meaningful ways for employees to connect more deeply with our work, including partnering with local communities to promote health equity and well-being initiatives, and prioritizing DEIB in many aspects of our decision making. We believe these efforts not only support an environment where everyone can thrive, but also make us even more effective in supporting the world’s good health and wellbeing.

Making Healthy Affordable

Amneal is an integral part of the U.S. health care system and works tirelessly to advance patient’s health through essential medicines. Each year, the Association for Accessible Medicines (AAM) releases a report outlining the value that generic and biosimilar medicines continue to bring to patients in the U.S. AAM publishes these findings to ensure policymakers, health care professionals, advocates and the public know the vital role that safe, effective, FDA-approved generics and biosimilars play in the health of our country.

The 2022 report, titled The U.S. Generic & Biosimilar Medicines Savings Report, analyzed the savings generated in 2021 for the U.S. market. In 2021, Amneal’s generic and biosimilars medicines were responsible for saving patients over $10 billion** in the U.S.

**Amneal’s generic savings in the U.S. in 2021 was calculated by taking the total national savings estimated by the Association for Accessible Medicines¹ and determining Amneal’s market share by volume, data of which was derived from IQVIA.


Did you know?¹

• Because of their lower cost and high value to patients, generics and biosimilars represent 91% of the prescriptions dispensed in the U.S.

• The U.S. health care system has saved more than $2.6 trillion in the last 10 years due to the availability of affordable generics and biosimilars.

Making Healthy Accessible

We are dedicated to providing safe and effective, high-quality medicines to those who need them most, when they need them. This commitment drives us to continually innovate and advocate for reduced barriers to patients’ access to the life-saving medicines they require. We recognize that providing affordable medicine is not enough; access must also be easy and available for patients in need. We are strong advocates for improving healthcare and reducing healthcare disparities, especially in underserved communities. By combining our innovative spirit with our commitment to advocacy, we believe we can make a meaningful difference in the lives of those we serve, and we remain dedicated to this mission.

A Spotlight on U.S. Advocacy

Amneal is committed to ensuring policies from FDA and Capitol Hill align with our shared goal of getting safe and effective high-quality lower-cost medicines to the patients who need them most. As the remaining large U.S.-based manufacturer of generic drugs, with a growing biosimilar portfolio, Amneal is a critical thought partner for policymakers as they develop policies or legislation that enable access.

“Amneal is committed to ensuring policies from FDA and Capitol Hill align with our shared goal of getting safe and effective high-quality lower-cost medicines to the patients who need them most. As the remaining large U.S.-based manufacturer of generic drugs, with a growing biosimilar portfolio, Amneal is a critical thought partner for policymakers as they develop policies or legislation that enable access.”

– Maryll Toufanian, Senior Vice President, Regulatory Strategy and Policy

Amneal continues to expand our presence in Washington, D.C. On Capitol Hill we are providing our expertise and input on new laws and policies that impact the generics and biosimilars industries. For example, we are helping lead the industry effort to develop proactive policies critical to addressing the underlying causes of drug shortages. We also are enhancing our role as a trusted voice of stakeholders before the U.S. Department of Health and Human Services, the Food and Drug Administration, and The Centers for Medicare and Medicaid Services. Good policies ensure better overall world health.

Amneal Supports Underserved and Uninsured Patients since 2012

Over 10 years ago, Amneal initiated a partnership with a not-for-profit organization called the Dispensary of Hope. Dispensary of Hope collects and distributes millions of dollars worth of medicines annually to pharmacies and safety-net clinics to dispense to low-income, chronically ill patients. We formed this partnership because we share an important mission: to make essential medicines accessible to all patients. Since then, we have touched hundreds of thousands of lives, and both organizations have grown tremendously along the way. To date, we have donated more than 20 million doses of medicines to U.S. patients in need.

Chirag Patel Named Chair of the Association for Accessible Medicines Board of Directors

From February 2022 to February 2023, Chirag Patel served as the Chair of the Association of Accessible Medicines (AAM) Board of Directors for 2022. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars. As manufacturers of 9 out of every 10 prescriptions dispensed in the U.S., AAM members are an integral and powerful part of the health care system. They believe in improving access to safe, quality, and effective medicine, ultimately helping more people in more places live healthier and longer lives.

“The generic and biosimilar medicines industry continues to deliver so much good for so many people, filling more than 90% of all prescriptions in the U.S. while only contributing 18% of the total spend,” said Chirag Patel. “As Board Chair, I am committed to working alongside my peers to meaningfully advance our critical work in providing safe, effective, reliable and affordable medicines to American patients.”
Investment in Research and Development (R&D)

We have one of the largest generics pipelines in the industry thanks to our dedicated and highly-accomplished R&D team. Our cadence of product innovation continued in 2022 as we shifted our efforts towards a wide array of complex pipeline products.

Our Specialty R&D team is advancing key pipeline projects and clinical activities that meet important medical needs and leverage Amneal’s strengths. In 2022, the team completed the development and submission of our first full clinical New Drug Application for IPX203, an extended-release capsule for the treatment of Parkinson’s Disease.

Amneal is committed to investing in R&D with the aim of delivering high-quality and innovative products. Our R&D activities represent a significant part our business, and our expenditures relate to the discovery, testing and development of new products, upfront payments and milestones and improving existing products. Additionally, it includes demonstrating product efficacy where applicable and regulatory compliance prior to launch.

R&D SPENDING

<table>
<thead>
<tr>
<th>Year</th>
<th>Spending</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020</td>
<td>$179.9 million</td>
</tr>
<tr>
<td>2021</td>
<td>$201.8 million</td>
</tr>
<tr>
<td>2022</td>
<td>$195.7 million</td>
</tr>
</tbody>
</table>

Extending Access and Affordability to International Markets

As we set our strategic long-term vision for Amneal, we continue to identify new opportunities to expand access to essential medicines globally by leveraging our diverse U.S. FDA approved product portfolio of complex generics, injectables, specialty and biosimilars. Looking ahead, we view 2023 as a foundational year in executing our international expansion strategy and have a dedicated team at Amneal focused on driving this area.

<table>
<thead>
<tr>
<th>GEOGRAPHY</th>
<th>DIRECT/PARTNER</th>
<th>STRATEGY AND STATUS</th>
</tr>
</thead>
</table>
| India     | Direct: building local presence | • Utilizing commercial team to launch products locally  
• Focusing on the hospital and specialty products market |
| Europe    | Partner: Orion Corporation | • Signed agreement in late 2022 to distribute complex generics |
| China     | Partner: Fosun Pharmaceuticals | • Expect first product approvals in 2023  
• 7 products filed with more planned over time |
| Canada    | Partner: Sterimax | • Signed agreement in early 2023 to distribute injectables |
| Rest of World | Partners: TBD | • Pursuing distribution agreements to enter select markets |

Contributing to the global agenda

In June, Chirag Patel, co-CEO, was appointed to the U.S. Department of Commerce’s U.S.-India CEO Forum to help advance the U.S.-India commercial agenda.
Our People

Workforce Representation

We lead Amneal from a people-first mindset, recognizing that it is our people who generate ideas, operate machinery and deliver success. Since our founding in 2002, we have focused on recruiting, empowering, incentivizing and rewarding employees who are passionately engaged in our mission to “make healthy possible”.

As of December 31, 2022, we had approximately 7,600 employees (“Employees”), excluding approximately 150 employees in our AvKARE segment. Of the Employees, approximately 2,400 employees were in the U.S. and approximately 5,200 employees were located outside of the U.S., primarily in India and Ireland. As a global employer, we hired approximately 2,000 Employees in 2022, and global turnover of those employees was approximately 19%.

<table>
<thead>
<tr>
<th>WORKFORCE REPRESENTATION</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total global employees</td>
<td>7,000</td>
<td>7,600</td>
</tr>
<tr>
<td>Global employees by department</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manufacturing</td>
<td>52%</td>
<td>52%</td>
</tr>
<tr>
<td>Quality</td>
<td>13%</td>
<td>12%</td>
</tr>
<tr>
<td>SG&amp;A</td>
<td>22%</td>
<td>23%</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>12%</td>
<td>13%</td>
</tr>
</tbody>
</table>

| Global employees by gender |   |   |
| Male                      | 19% | 18% |
| Unknown                   | 81% | 82% |
| Female                    | 0.1%| 0.05%|
| Non-binary                | 0.01%| 0.01%|

| Global employees by age   |   |   |
| Under 30                  | 15%| 14% |
| Over 50                   | 27%| 26% |
| 30-50                     | 58%| 60% |
Strength in Diversity

At Amneal, we pride ourselves on promoting diversity in the workplace. We recognize the importance of having a varied workforce and appreciate the knowledge, expertise, strength, and energy everyone — regardless of gender identity, age, race or ethnicity — brings to our company.

In 2022, we saw a 4.1% increase of women in leadership* within the U.S. workforce and an 8% increase within Amneal’s Board of Directors (the “Board”). While we’re happy with our progress in the U.S., we recognize that we still have work to do to enhance gender diversity in India. We are committed to increasing women in our global workforce through the launch of our ERG program and leadership diversity trainings as well as rolling out new and enhanced programs that support women in the workplace.

<table>
<thead>
<tr>
<th>Gender Diversity</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>39%</td>
<td>40%</td>
</tr>
<tr>
<td>India</td>
<td>8%</td>
<td>8%</td>
</tr>
<tr>
<td>Ireland</td>
<td>41%</td>
<td>37%</td>
</tr>
<tr>
<td>U.S. Leadership*</td>
<td>27%</td>
<td>31%</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>10%</td>
<td>18%</td>
</tr>
</tbody>
</table>

In 2022, 42.3% of U.S. Leadership identified as diverse talent**, a 2.6% increase year-over-year and over 72% of our U.S. workforce identified as diverse talent, an increase of 3.8%.

<table>
<thead>
<tr>
<th>U.S. Diverse Talent</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. Leadership*</td>
<td>40%</td>
<td>42%</td>
</tr>
<tr>
<td>U.S. Employees</td>
<td>69%</td>
<td>72%</td>
</tr>
</tbody>
</table>

*Leadership is defined at the level of Director and above in the U.S.
**Diverse talent is defined by EEO-1 categories for people who identify as Asian, Black or African American, Hispanic or Latino, Native Hawaiian or Other, Pacific Islander, Two or More Races, and Other.
Initiatives to Recruit and Retain Diverse Talent

In the U.S., Amneal partners with eQuest, which posts our job openings to U.S. state job banks and sites focused on protected veterans and individuals with disabilities. In India, our Talent Acquisition team leads four initiatives to recruit diverse talent by region, belief, domicile, and gender including: Campus Connect, Inter Country Walk In, Employment Exchange (National Skills Database), and Inter Country Job Boards.

Recruiting and retaining scientists and R&D personnel is critical to Amneal’s success. In the U.S., Amneal hosts both virtual and in-person hiring events, some of which are targeted towards scientist and R&D personnel. We have done this at various locations, including Piscataway, NJ and Brookhaven, NY. These events have been open to both registered and previously applied applicants, as well as walk-ins interested in learning more about Amneal. These events have been advertised locally, as well as posted to our career and LinkedIn pages.

Part of the reason we have been able to grow so successfully over the last 20 years is our willingness to not only learn but learn together. So as part of our Amneal Leadership Lab, we conducted an insightful virtual workshop on the importance of DEIB in the workplace.

Our goal is to develop enhanced perspectives about diversity and our individual differences, fostering a sense of how important it is to recognize and celebrate those differences because they can help nurture a feeling of belonging for all. We want members of our team to feel that they belong so that they can bring the best version of themselves to work every day, and help create more productive teams that contribute meaningful ideas and strengthen our culture.

In 2023, we plan to expand the availability of these workshops and trainings for our employees.
A Focus on Gender Equality

Creating and sustaining a culture of inclusion requires bringing together and supporting diverse people with unique perspectives. We are proud to share the launch of our first ERG, AmnealWomen. ERGs will serve as a next important step in enhancing our DEIB strategy, offering new leadership opportunities for employees and strengthening employee engagement.

AmnealWomen’s mission is to build an inclusive community that upholds Amneal’s values by creating a network of diverse women and allies, providing resources and opportunities to learn from each other, spotlighting those dedicated to advancing the organization and cultivating relationships in support of women’s growth, advancement and success.

In recent years, increased visibility around the importance of diversity, inclusion and belonging in the workplace and recognition of its benefits have prompted many companies to reflect on their own initiatives: What programs truly contribute to a culture of community and connection? How do we create an environment where all employees thrive? Considering these questions led us to launch a U.S. pilot program with AmnealWomen, our first employee resource group. We’ve been delighted with the overwhelmingly positive response and have leaned into this momentum by expanding the program to our colleagues in India.

– Emily Parlapiano,
Sr. Director, ESG Programs and Reporting

Culture of Learning, Listening and Acknowledgement

Amneal’s evolution from a generic company to one that is now diversified in increasingly complex areas has also driven a substantial investment in our people. To be successful in new areas of business, we also needed to help colleagues think and act differently. Our innovative Amneal Leadership Lab is helping us do just that by introducing outside perspectives, world-class leadership principles, digital learning resources and dynamic opportunities to learn from each other. We are seeing tremendous success in colleagues inspiring and elevating each other to create an even stronger Amneal culture and company.

– Steve Sost,
Vice President, Internal Communications

Learning and Development

We inspire our employees to continuously elevate their careers by offering opportunities to expand their skills through education, mentoring and the continuous evolution of our Learning and Development platform.

Our open culture is based on the belief that everyone can be a leader, and we live that belief every day. We know that everyone can embrace leadership concepts and leverage them, whether it’s learning in our Amneal Leadership Lab or taking advantage of our LinkedIn Learning modules; we openly support and encourage all our employees to be leaders in their own work. We launched the Amneal Leadership Lab in 2021 for 200 senior and mid-level managers to help arm them with the tools they need to meet the challenges of the modern workplace. We expanded the initiative later in 2021 to include LinkedIn Learning. Through curated learning paths, we’re providing unique opportunities for all colleagues to engage in our individual and organizational leadership growth journeys.

In 2022, we took the program further by introducing the concept of cohorts. These smaller discussion groups present an opportunity for those who have engaged in learning modules, including senior leadership, to come back and share what they have learned with other employees. Hundreds of employees participated in modules that included Building Team Relationships, Driving Team Performance, Strategic Agility and Harassment training both online and in the classroom.
**Key 2022 L&D stats:**

<table>
<thead>
<tr>
<th></th>
<th>U.S.</th>
<th>INDIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of licenses</td>
<td>2,300</td>
<td>197</td>
</tr>
<tr>
<td>Percentage of active licenses</td>
<td>37%</td>
<td>458%</td>
</tr>
<tr>
<td>Number of active licenses</td>
<td>844</td>
<td></td>
</tr>
<tr>
<td>Number of usage hours</td>
<td></td>
<td>458</td>
</tr>
<tr>
<td>Trainings covering</td>
<td>93</td>
<td>107</td>
</tr>
<tr>
<td>Topics</td>
<td>19</td>
<td>54</td>
</tr>
</tbody>
</table>

**LinkedIn Learning**

**AmnealListens**

In 2022, we launched Amneal Listens, an employee listening strategy powered by a reputable third-party tool focused on strengthening engagement. We leveraged the survey tool to poll our top 200 leaders to assess the strength of our human capital strategies and identify areas for improvement. We also released an employee engagement pulse survey to approximately 3,500 of our global employee base.

The short pulse survey was designed to measure 1) employees’ connection of individual contributions to impact, 2) belief in the strategy, 3) manager communications, 4) confidence in the company’s future, and 5) degree of feeling valued. Our leadership was encouraged by our engagement score and will look to set a go-forward baseline with our next survey. We intend to make the next survey available for all employees to participate.

Looking ahead, we will continue to expand our Amneal Listens strategy via an annual employee engagement survey as well as various strategically focused ad hoc surveys throughout the year.

**Acknowledgement**

Our work has a profound impact on people’s lives, and we believe it is important to acknowledge the valuable and life-changing work our colleagues do.

Our 2nd annual CEO Awards took place in 2022, recognizing employees nominated by their managers who have made exceptional individual contributions to the organization. Twelve employees were honored out of the 75 nominated and received this recognition personally from our co-CEOs Chirag and Chintu Patel. These awards are a vital part of our employee experience, as they represent our recognition of the work our people do every day to make healthy possible.

In addition to this annual celebration of our people, Amneal has regular, ongoing recognition awards to acknowledge employees and individual teams on a monthly, quarterly and annual basis. We also have daily recognition through our Amneal Applause program. For our sales team in the U.S., we have a special Circle of Excellence Award for honoring these dedicated professionals for the work they do in educating physicians about our products.
Giving Back Globally

As we continue to expand our company’s footprint, capabilities and team, we are also strengthening our commitment to operating sustainably. But that does not just mean being good stewards of the environment and using natural resources safely and responsibly; it also means giving back to the communities where we work.

To show support for our communities, Amneal celebrated its 20th Anniversary by hosting our first-ever global employee volunteering event. In October 2022, colleagues in the U.S., India and Ireland packed hygiene kits, composed of such items as soap, toothpaste and shampoo, for distribution to local community groups.

Employees in the U.S. partnered with Heart to Heart International, a global humanitarian organization with a mission to improve healthcare around the world by ensuring quality care in under-resourced communities and disaster situations. Amneal colleagues packed and distributed 6,000 hygiene kits to those in need in New York, New Jersey and Kentucky.

In India, Amneal teamed up with the Irada Foundation and the Niswarth Children foundation. The Irada Foundation’s work is aimed at improving overall quality of life of communities through long term and sustainable interventions in the areas of access to health care and medical services, nutritious food distribution programs, disaster responses and more. The Niswarth Foundation is committed to bringing fresh water, sanitation, nutrition and education to underprivileged children. Colleagues packed more than 550 nutritional kits to distribute to pregnant women across five districts.

In Ireland, Amneal joined with Cuan Soar, a women’s refuge in Clonmel. Cuan Soar is a Safe Haven, offering support to women and children who are experiencing domestic violence. The team packed 150 hygiene kits that contained towels, face cloths, toothbrushes and toothpaste, soap, wipes, deodorant, shower gel, shampoo, women’s hygiene products and socks.

- Contributed $50,000 to support Ukrainian humanitarian efforts and provide critical supplies.
- We responded to the humanitarian crisis in Ukraine by joining as an Americares Emergency Response Program partner, donating $50,000 in funding, critical medicines and 12 pallets of basic needs supplies. In 2022, Amneal product was included in 15 relief shipments to Ukraine.
- Hundreds of employees supported Parkinson’s research through our AmWell Virtual Step Challenge and NYC’s Central Park Walk.
- Colleagues in India planted more than 2,000 trees in local communities.
- Since launching our partnership with American Corporate Partners (ACP) in 2020 — a non-profit dedicated to assisting veterans and active-duty military spouses find meaningful careers — 35 Amneal volunteers have mentored 57 ACP proteges.
- We participated in our third annual Toys for Tots campaign in the U.S., raising and donating over $25,000 and collecting donated toys at each of our U.S. locations.
Environment

We take a proactive approach to our environmental impact and believe that every company has a role to play in reducing our impact on the planet. Our commitment includes environmental protection, creating environmental awareness, monitoring our company’s environmental performance, reducing emissions, releases, and waste, and using natural resources more efficiently.
We are strengthening our commitment to being good stewards of the environment and operating in a safe and environmentally responsible manner by convening a Global Environmental Working Group (EWG) to address the climate crisis and work toward aligning our disclosures with the Task Force on Climate-Related Financial Disclosures (TCFD) while staying informed of the changing regulatory requirements.

Global Environmental Working Group

In 2021, we committed to convening a global Environmental Working Group (EWG) and in 2022, that group was introduced to the organization. The EWG is comprised of senior leaders from key global functions, including Environmental Health and Safety (EHS), Operations, Supply Chain, Finance, Legal, and HR. The group is led by the Senior Director, ESG and meets approximately three times annually.

The EWG's goal is to minimize our environmental impact, ensure appropriate oversight of global environmental impacts and promote sustainable practices across all aspects of our operations. The group is committed to advancing our organization’s environmental sustainability efforts through collaboration, education, and goal-setting.

The goals for the group include:

- Developing and implementing sustainable practices that reduce our environmental impact and support our organization’s long-term sustainability goals;
- Educating employees on environmental issues and encouraging them to make sustainable choices;
- Collaborating with internal departments and external partners to promote sustainable practices and reduce our environmental impact;
- Monitoring and reporting on our progress towards meeting our sustainability goals and recommending strategies to improve our performance; and
- Advocating for policies and practices that promote environmental sustainability and align with our organization’s values and objectives.

This dedication to cross-functional collaboration led us to kick-off our first project: assessing our existing environmental data collection capabilities site by site globally. As a direct result of that assessment, we decided to initiate a second phase of the project which included a manual inventory of utility/consumption data across our global footprint, enabling us to work towards setting a global baseline and preparing for increased reporting directives. Details on the next phase of this project are included below (Tracking our Carbon Footprint).

This collaborative forum also provided EHS leaders with the opportunity to share best practices from their sites as well as key technologies that enable real-time monitoring and enhanced root cause analysis. This led to a project focused on implementing a common EHS software platform to be used in all sites across the U.S, India, and Ireland. We look forward to sharing additional details on these key projects in our next update.

PROGRESS & HIGHLIGHTS FOR 2022

- Created and convened global EWG
- Created an initial manual Greenhouse Gas (GHG) emissions inventory
- Onboarded carbon accounting vendor
- Initiated rollout of global health and safety system
Tracking our Carbon Footprint

Our organization recognizes the importance of understanding and mitigating our carbon footprint on a global scale. After identifying a data collection gap in global carbon emissions, we selected a carbon accounting solution to help systematize our data collection, analysis and goal setting efforts. We are in the process of establishing the necessary organizational structure, data collection requirements specific to our business, and standard operating procedures. Once established, we will gain capability to calculate our Scope 1 and Scope 2 GHG emissions baseline.

This platform will enable us to turn consumption and emissions data into actionable steps towards a lower carbon footprint, and we believe it will enable us to create global solutions by consistently monitoring and measuring across all our sites.

Enhancing Environmental, Health and Safety (EHS)

Health, safety, and well-being management is the responsibility of site management. At our global facilities, local managers are responsible for health and safety compliance and performance, and are supported by EHS and Operations professionals who drive local implementation of health and safety programs and initiatives.

Our New York and New Jersey locations host monthly EHS Steering Committee meetings. The following topics are addressed:

- Any issues that arise from weekly internal inspections
- Key statistics from our onsite workplace health partner, ATI Worksite Solutions
- Existing and new safety standard operating procedures (SOP)
- Status updates on training requirements
- Key OSHA health and safety metrics by facility including Total Recordable Incident Rate (TRIR) and others
- General promotion of safety culture and awareness to employees including a safety topic of the month
Making Healthy Possible for our Planet

Environmental Success Stories from our Global Facilities
The incremental investments and changes we are making not only help reduce our impacts on the planet, but also reduce our operating costs and make us more flexible, resilient, and productive.

Recycling Efficiencies
Three of our largest distribution warehouse centers for our Generics and Specialty products are located in the state of Kentucky. Each year, they handle significant quantities of cardboard and plastic at each location from packaging and shipping materials. Always looking for new ways to reduce waste, our warehouses save thousands of pounds of cardboard and plastic each year, keeping them from landfills. In 2022, these distribution centers recycled more than 21,200 pounds of cardboard and 23,000 pounds of shrink-wrap plastic from pallets.

In 2022, our colleagues from the U.S. (Kentucky) and India (multiple sites) campaigned to swap India’s wooden Euro pallets to standard U.S. pallets for product distribution. The Euro pallets could not be reused in the U.S. resulting in land field waste but with this swap, we are now able to reuse approximately 13,000 additional pallets in 2023 and beyond.

Promoting Environmental Responsibility in India
Our colleagues in India partnered with government and community organizations to lead a 100-day public education and awareness campaign focused on minimizing the use of plastic and properly collecting and disposing of waste. Amneal colleagues played a hands-on role throughout the campaign by organizing plastic waste collection initiatives in local villages and introducing educational programs at local primary schools.

In addition, our talented engineering team at our RAKS Dahej site put new ideas into action by proactively designing and operating an onsite steam condensate recovery system. Through innovative technology, the team improved the efficiency and effectiveness of the facility’s boiler system and reduced water treatment costs as well as freshwater consumption.

Seeing the Light in Ireland
In 2022, our Ireland facility completed an energy improvement project with the goal of replacing fluorescent lab lighting with more energy-efficient LED panels. LED panel lights are a great alternative to fluorescents because they not only provide high-quality light, but also dissipate heat uniformly and are a much more environmentally friendly option for saving energy while also offering lower maintenance costs.

Since implementing new LEDs, the Ireland team has seen substantial impacts. In 2022 alone, the installation is estimated to have saved the equivalent of US$11,840 and 53,350-kilowatt hours of energy. In addition, the upgrade to LEDs is expected to pay for itself in less than two years.

Looking to 2023, our Ireland team has set 5% reduction targets for gas consumption, electricity consumption as well as a 5% reduction in CO2 emissions. Two projects are planned for the year including the installation of Solar PV Panels and EV charging points in the company carpark to achieve those goals.
Governance

We are committed to conducting every aspect of our business in an ethical, open, and honest manner and in full compliance with the law, both in letter and in spirit.
Good governance is the foundation on which we build the base of our ESG program. Governance sets the groundwork for both the social and environmental aspects of our ESG philosophy by providing the structure and parameters we use to guide us forward. Governance also helps guide our goal setting by outlining what we value most and, therefore, where we will concentrate our efforts in doing our part to make healthy possible while aligning ourselves with ESG best practices.

PROGRESS & HIGHLIGHTS FOR 2022

- Appointed our second female board member
- Completed our second board diversity survey
- Aligned our Global Supplier Code of Conduct with the United Nations Guiding Principles
- Aligned our 2022 ESG update with the Sustainability Accounting Standards Board (SASB)

Board Diversity

We aim to further our commitment to good governance practices and place a high priority on ensuring our Board features members with diverse backgrounds and unique skill sets.

The Board does not have a formal policy on board diversity as it relates to the selection of nominees for the Board. However, the Board believes that diversity and a variety of experiences and viewpoints should be represented. In selecting a director nominee, the Nominating and Corporate Governance Committee focuses on skills, viewpoints, expertise, or background that would complement the existing Board. The Nominating and Corporate Governance Committee seeks to identify candidates representing diverse experience at policy-making levels in business, management, marketing, finance, regulatory affairs, human resources, communications, and other areas that are relevant to our activities.

In addition, one of the many factors that the Board and the Nominating and Corporate Governance Committee carefully considers is the importance of ethnic and gender diversity. The Nominating and Corporate Governance Committee assesses its effectiveness in this regard when evaluating the composition of the Board.

We place a high priority on fostering a Board that reflects expanded experiences and perspectives, including those arising out of diversity related to race, ethnicity, gender, sexual orientation, and areas of expertise. Consistent with this philosophy, we have a diversified Board.

Of our 11 members, nine have disclosed their gender and demographic backgrounds, which consists of seven male and two female Board members, with two Board members who identify as Asian, and seven who identify as Caucasian. One Board member identifies as LGBTQ+.

Learn more about how Amneal approaches Director Nominations.
We strive to conduct all aspects of our business in accordance with the highest standards of business ethics and to comply with applicable laws and regulations that govern our regulated industry.

As part of this effort, Amneal has established an enterprise-wide Corporate Compliance Program that is designed to ensure that the organization complies with our obligations under applicable law, company policy, and industry guidance. The Corporate Compliance Department helps guide us through training, effective and timely communication, risk identification measures, and mitigation strategy. Amneal’s Corporate Compliance Department routinely conducts auditing and monitoring of business activities (in cooperation with Amneal’s Internal Audit team) to assess adherence to company policies, identify potential training needs, and ascertain the need for policy development or modification.

Oversight of the Compliance Program
Amneal’s VP, Corporate Compliance has primary responsibility for development and implementation of Amneal’s Corporate Compliance Program, including drafting policies and procedures, training, monitoring, performing investigations, and responding to identified problems. The VP, Corporate Compliance provides periodic reports on the operation of the Compliance Program to Amneal’s Compliance Committee and the Audit Committee of the Board the body with oversight of Amneal’s Compliance Program.

Compliance Education and Training
Education is a key element of Amneal’s Corporate Compliance Program, and as such we are committed to implementing a training program designed to provide our employees with information needed to execute their job responsibilities in an effective and compliant manner and to help employees better understand the impact of their actions on Amneal and society as a whole. Upon joining Amneal, employees receive comprehensive training on requirements that pertain to our industry, general compliance matters and their specific job functions. Employees continue to receive compliance training on at least an annual basis and when relevant changes are made to the policies or regulations that govern their business conduct.

Amneal reviews and updates its training programs periodically to increase clarity and effectiveness and to identify areas where additional training is needed.

Global Supplier Code of Conduct
Suppliers are an integral part of Amneal’s overall success, and we expect all suppliers conducting business with our company to comply with our Global Supplier Code of Conduct and all applicable laws and regulations in the locations where they conduct business.

In 2022, we updated Amneal’s Global Supplier Code of Conduct to further align the requirements in accordance with the United Nations Guiding Principles. The Ten Principles of the United Nations Global Compact covers the topics of human rights, labor, environment, and anti-corruption, and are derived from the:
- Universal Declaration of Human Rights,
- International Labour Organization’s Declaration on Fundamental Principles and Rights at Work,
- Rio Declaration on Environment and Development, and
- United Nations Convention Against Corruption.
Cybersecurity

Like so many other industries, cybersecurity is a top concern of the pharmaceutical industry. Our employees, partners, suppliers and other third parties rely on us to be responsible custodians of their information. Maintaining their trust is critical to our success and fundamental to upholding our company values.

We rely on the NIST Cybersecurity Frameworks developed by The National Institute of Standards and Technology (NIST CSF) as the foundation of our security program. Leveraging the five core functions of identify, protect, detect, respond, and recover enables Amneal to leverage best practices in continuously improving our ability to mitigate risks and respond to attacks.

Built from practices known to help organizations improve their cybersecurity posture, the NIST CSF helps to better integrate and align cybersecurity risk management with broader enterprise risk management processes. Based on this framework, we assess our systems frequently and report to the Audit Committee of our Board on a semi-annual basis.

In 2022, we delivered improvements across the identify, protect, detect, and respond categories, and remained steady in the recovery category. Enhancements came from new tools and services that improved our efforts on third-party risk management and cyber risk management, increases in user awareness training, and the expansion of multi-factor authentication. We onboarded an innovative and best-in-class cyber intelligence platform that looks from the outside in to detect and identify technical risks, provides our security experts with the accurate and comprehensive cyber intelligence, and provides us with a clear view of any vulnerabilities in our online environment.

In addition, we have worked in concert with the Compliance Department to incorporate risk assessments and audits into our risk management policy for new vendors, along with mandatory cybersecurity training.

Forward-Looking Statements

Certain statements contained in this Environmental, Social and Governance Report regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future, including statements regarding our ESG goals, commitments and programs and other business plans, initiatives and objectives. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates” and similar words are intended to identify estimates and forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Amneal. The forward-looking statements contained herein are subject generally to the risks and uncertainties that are described from time to time in Amneal’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in Amneal’s most recent Annual Report on Form 10-K and in subsequent quarterly and period reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.
# Sustainability Accounting Standards Board (SASB) 2022 Index

Amneal is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. This SASB Index is aligned with the Biotechnology and Pharmaceuticals Standard and includes our response to the metrics that apply to our business.

## Biotechnology & Pharmaceuticals Standard

<table>
<thead>
<tr>
<th>TOPIC</th>
<th>METRIC/CODE</th>
<th>DISCLOSURE LOCATION/RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Number of FDA Sponsor inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI): HC-BP-210a.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries: HC-BP-210a.3</td>
<td>All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs)</td>
</tr>
<tr>
<td>Access to Medicines</td>
<td>Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index: HC-BP-240a.1</td>
<td>2022 ESG Report: Making Healthy Accessible, Page 16</td>
</tr>
<tr>
<td></td>
<td>List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP): HC-BP-240a.2</td>
<td>No Amneal products are on the list at time of reporting</td>
</tr>
<tr>
<td>Affordability &amp; Pricing</td>
<td>Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period: HC-BP-240b.1</td>
<td>All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs)</td>
</tr>
<tr>
<td></td>
<td>Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year: HC-BP-240b.2</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year: HC-BP-240b.3</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System: HC-BP-250a.2</td>
<td>FDA Adverse Event Reporting System</td>
</tr>
<tr>
<td></td>
<td>Number of recalls issued, total units recalled: HC-BP-250a.3</td>
<td>FDA Recall Database</td>
</tr>
<tr>
<td></td>
<td>Total amount of product accepted for take-back, reuse, or disposal: HC-BP-250a.4</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type: HC-BP-250a.5</td>
<td>Not reported</td>
</tr>
<tr>
<td>Counterfeit Drugs</td>
<td>Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting: HC-BP-260a.1</td>
<td>2022 ESG Report: Distribution and Supply Chain, Page 12</td>
</tr>
<tr>
<td></td>
<td>Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products: HC-BP-260a.2</td>
<td>2022 ESG Report: Distribution and Supply Chain, Page 12</td>
</tr>
<tr>
<td></td>
<td>Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products: HC-BP-260a.3</td>
<td>All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs)</td>
</tr>
<tr>
<td>TOPIC</td>
<td>METRIC/CODE</td>
<td>DISCLOSURE LOCATION/RESPONSE</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Ethical Marketing</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with false marketing claims: HC-BP-270a.1</td>
<td>All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs)</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing promotion of off-label use of products: HC-BP-270a.2</td>
<td>In accordance with Amneal’s Code of Conduct and supporting policies. Amneal follows applicable laws in the markets it serves, adhering at all times to product labeling requirements and promoting only uses that have been approved by regulatory authorities. Amneal prohibits off-label information, with limited exceptions as permitted and in accordance with applicable laws. Amneal further requires employees to report suspected violations of applicable laws, and any suspected violations of Amneal policies and procedures, directly to a supervisor, Corporate Compliance, Legal, or through the Amneal Ethics &amp; Compliance hotline, Amtegrity.</td>
</tr>
<tr>
<td>Development &amp; Retention</td>
<td>(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others: HC-BP-330a.2</td>
<td>2022 Annual Report Form 10-K: Page 18</td>
</tr>
<tr>
<td>Supply Chain Management</td>
<td>Percentage of (1) entity’s facilities and (2) Tier I suppliers’ facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients: HC-BP-430a.1</td>
<td>Not reported</td>
</tr>
<tr>
<td>Business Ethics</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery: HC-BP-510a.1</td>
<td>All material, legal, and regulatory issues are reported in our annual and quarterly filings (10-K and 10-Qs)</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing interactions with health care professionals: HC-BP-510a.2</td>
<td>In accordance with Amneal’s Code of Conduct and supporting policies. Amneal follows applicable laws in the markets it serves, adhering at all times to product labeling requirements and promoting only uses that have been approved by regulatory authorities. Amneal prohibits off-label information, with limited exceptions as permitted and in accordance with applicable laws. Amneal further requires employees to report suspected violations of applicable laws, and any suspected violations of Amneal policies and procedures, directly to a supervisor, Corporate Compliance, Legal, or through the Amneal Ethics &amp; Compliance hotline, Amtegrity.</td>
</tr>
<tr>
<td>Activity Metrics</td>
<td>Number of patients treated: HC-BP-000.A</td>
<td>Not reported</td>
</tr>
<tr>
<td></td>
<td>Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3): HC-BP-000.A</td>
<td>(1) Our Portfolio, (2) Research and Development</td>
</tr>
</tbody>
</table>